CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Statera Biopharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Statera Biopharma Inc
2537 Research Boulevard, Suite 201
Phone: (716) 849-6810p:716 849-6810 FORT COLLINS, CO  80526  United States Ticker: STABSTAB
On 5/3/2024, the Securities and Exchange Commission (SEC) charged BF Borgers CPA PC and its owner, Benjamin F. Borgers, with significant violations of Public Company Accounting Oversight Board (PCAOB) standards across more than 1,500 SEC filings from January 2021 to June 2023. The charges included falsely representing compliance with PCAOB standards to clients, fabricating audit documentation, and inaccurately stating compliance in audit reports. According to the SEC's order, of 369 BF Borgers' clients whose public filings from January 2021 through June 2023 incorporated the firm's audits and reviews, at least 75 percent of the filings incorporated audits and reviews that did not comply with PCAOB standards. The financials in this report may include past audits and reviews conducted by BF Borgers CPA PC that are deemed not compliant with PCAOB standards.
Business Summary
Statera BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body’s immune system and restore homeostasis. It has platform of toll-like receptor (TLR) agonists with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. The Company is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to potential expansion into fibromyalgia and multiple sclerosis.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202212/31/2021YesYesYesYesYes

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer Michael K.Handley 51 7/27/2021 7/27/2021
Interim Chief Financial Officer, Executive Vice President - Finance, Interim Chief Accounting Offic ChristopherZosh 47 5/27/2022 1/1/2019
Chief Technology Officer Robert W.Buckheit 62 7/27/2021 7/27/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
CBLI
Cytocom Subsidiary Inc.
ImQuest BioSciences, Inc.
6 additional Business Names available in full report.

General Information
Number of Employees: 46 (As of 12/31/2021)
Outstanding Shares: 71,416,038 (As of 2/14/2023)
Shareholders: 1,800
Stock Exchange: OTC
Federal Tax Id: 200077155
Fax Number: (716) 849-6820


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, October 20, 2024